Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Short-term Investments (2016 - 2019)

Akebia Therapeutics (AKBA) has disclosed Short-term Investments for 3 consecutive years, with $245000.0 as the latest value for Q4 2019.

  • On a quarterly basis, Short-term Investments fell 99.58% to $245000.0 in Q4 2019 year-over-year; TTM through Dec 2019 was $245000.0, a 99.58% decrease, with the full-year FY2019 number at $245000.0, down 99.58% from a year prior.
  • Short-term Investments was $245000.0 for Q4 2019 at Akebia Therapeutics, down from $22.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $240.1 million in Q3 2017 to a low of $245000.0 in Q4 2019.
  • A 3-year average of $142.7 million and a median of $169.7 million in 2017 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: surged 42.72% in 2018, then plummeted 99.58% in 2019.
  • Akebia Therapeutics' Short-term Investments stood at $174.8 million in 2017, then plummeted by 66.57% to $58.4 million in 2018, then tumbled by 99.58% to $245000.0 in 2019.
  • Per Business Quant, the three most recent readings for AKBA's Short-term Investments are $245000.0 (Q4 2019), $22.7 million (Q3 2019), and $49.6 million (Q2 2019).